Evidence map›Paper›PMID 37024146›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2023

Dopamine Receptor D1 Is Exempt from Transforming Growth Factor

Ashley Y Gao, Ana M Diaz Espinosa, Ba Bao N Nguyen, Patrick A Link, Jeffrey Meridew, Dakota L Jones, Daniel F Gibbard, Daniel J Tschumperlin, Andrew J Haak

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. The Role of the Nervous System in Lung Disease.Current neurology and neuroscience reports · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Effective Synthesis of Dopamine Dimer.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2026
    Article
  7. Mechanistic basis for the antifibrotic actions of cAMP-based therapies.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  8. Review
  9. Review
  10. Pulmonary Fibrosis-Focusing on the Future: Aspen Lung Conference 2024 Summary.American journal of respiratory cell and molecular biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ashley Y GaoDepartments of Physiology and Biomedical Engineering (A.M.D.E., P.A.L., J.M., D.L.J., D.J.T., A.J.H.), Ophthalmology (A.Y.G.), and Molecular Pharmacology and Experimental Therapeutics (B.B.N.N., D.F.G., A.J.H.), Mayo Clinic, Rochester, Minnesota.
Ana M Diaz EspinosaDepartments of Physiology and Biomedical Engineering (A.M.D.E., P.A.L., J.M., D.L.J., D.J.T., A.J.H.), Ophthalmology (A.Y.G.), and Molecular Pharmacology and Experimental Therapeutics (B.B.N.N., D.F.G., A.J.H.), Mayo Clinic, Rochester, Minnesota.
Ba Bao N NguyenDepartments of Physiology and Biomedical Engineering (A.M.D.E., P.A.L., J.M., D.L.J., D.J.T., A.J.H.), Ophthalmology (A.Y.G.), and Molecular Pharmacology and Experimental Therapeutics (B.B.N.N., D.F.G., A.J.H.), Mayo Clinic, Rochester, Minnesota.
Patrick A LinkDepartments of Physiology and Biomedical Engineering (A.M.D.E., P.A.L., J.M., D.L.J., D.J.T., A.J.H.), Ophthalmology (A.Y.G.), and Molecular Pharmacology and Experimental Therapeutics (B.B.N.N., D.F.G., A.J.H.), Mayo Clinic, Rochester, Minnesota.
Jeffrey MeridewDepartments of Physiology and Biomedical Engineering (A.M.D.E., P.A.L., J.M., D.L.J., D.J.T., A.J.H.), Ophthalmology (A.Y.G.), and Molecular Pharmacology and Experimental Therapeutics (B.B.N.N., D.F.G., A.J.H.), Mayo Clinic, Rochester, Minnesota.
Dakota L JonesDepartments of Physiology and Biomedical Engineering (A.M.D.E., P.A.L., J.M., D.L.J., D.J.T., A.J.H.), Ophthalmology (A.Y.G.), and Molecular Pharmacology and Experimental Therapeutics (B.B.N.N., D.F.G., A.J.H.), Mayo Clinic, Rochester, Minnesota.
Daniel F GibbardDepartments of Physiology and Biomedical Engineering (A.M.D.E., P.A.L., J.M., D.L.J., D.J.T., A.J.H.), Ophthalmology (A.Y.G.), and Molecular Pharmacology and Experimental Therapeutics (B.B.N.N., D.F.G., A.J.H.), Mayo Clinic, Rochester, Minnesota.
Daniel J TschumperlinDepartments of Physiology and Biomedical Engineering (A.M.D.E., P.A.L., J.M., D.L.J., D.J.T., A.J.H.), Ophthalmology (A.Y.G.), and Molecular Pharmacology and Experimental Therapeutics (B.B.N.N., D.F.G., A.J.H.), Mayo Clinic, Rochester, Minnesota.
Andrew J HaakDepartments of Physiology and Biomedical Engineering (A.M.D.E., P.A.L., J.M., D.L.J., D.J.T., A.J.H.), Ophthalmology (A.Y.G.), and Molecular Pharmacology and Experimental Therapeutics (B.B.N.N., D.F.G., A.J.H.), Mayo Clinic, Rochester, Minnesota haak.andrew@mayo.edu.
Mayo Clinic · USWinnMed · US

Funding

Mechanobiology of Lung FibrosisR01HL092961 · NHLBI · MAYO CLINIC ROCHESTER · PI Daniel J. Tschumperlin · 2009 to 2026
$8.0M
Optimization of fibroblast-selective inhibitors of YAP/TAZ as novel therapeutics for Pulmonary FibrosisR61HL161804 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI HAAK, ANDREW JON, HEYNEN-GENEL, SUSANNE · 2022 to 2023
$1.3M
NHLBI NIH HHS R01 HL092961NHLBI NIH HHS R61 HL161804
6 · The paper itself

Abstract

Pulmonary fibroblasts are the primary producers of extracellular matrix (ECM) in the lungs, and their pathogenic activation drives scarring and loss of lung function in idiopathic pulmonary fibrosis (IPF). This uncontrolled production of ECM is stimulated by mechanosignaling and transforming growth factor beta 1 (TGF-

Indexed as

Idiopathic Pulmonary FibrosisTransforming Growth Factor beta1FibroblastsHumansLungReceptors, DopamineReceptors, Dopamine D1Receptors, G-Protein-CoupledTransforming Growth Factor betaDRD1 protein, humanReceptors, DopamineReceptors, Dopamine D1Receptors, G-Protein-CoupledTransforming Growth Factor betaTransforming Growth Factor beta1

Identifiers

PMID37024146
PMCPMC10449101
OpenAlexW4362660248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.